The immunohistochemical expression of cell cycle proteins p16, cyclin D1, and pRb was assessed in 112 benign and malignant melanocytic tumors and correlated with tumor progression, prognosis, and outcome. Comparing benign and malignant tumors, there were significant differences in the median score for all 3 proteins, with decreased p16 (P = .000001), increased cyclin D1 (P = .01), and increased pRb in melanomas (P = .01). There was a progressive loss of expression of p16 with progression from benign naevi to primary melanomas and to metastases. p16 was significantly decreased in primary tumors from melanoma patients who developed recurrent disease (P = .0000013). Cyclin D1 and pRb showed a progressive increase in expression from benign to malignant tumors but with relative decreases in the more advanced tumors (thick primaries and metastatic melanomas). Alterations in cell cycle proteins involved in G1/S transition are implicated in melanocytic tumor progression and have a potential role in diagnosis and prognostication.
Michalides R.Cell cycle regulators: role in etiology, prognosis and treatment in cancer. Ann Oncol. 2002;13 Suppl 4:39.
3.
Li W., Sanki A., Karim RZ, et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 2006;38(4):287-301.
4.
Sauroja I., Smeds J., Vlaykova T., et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma . Genes Chromosomes Cancer. 2000;28(4):404-414.
5.
Bhatt KV, Hu R., Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene. 2007;26(7): 1056-1066.
6.
Pei XH, Xiong Y.Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene. 2005;24(17):2787-2795.
7.
Korabiowska M., Ruschenburg I., Betke H., et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma . Pathobiology. 2001;69(5):274-280.
8.
Sauter ER, Yeo UC, von Stemm A., et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62(11):3200-3206.
9.
Bhatt KV, Spofford LS, Aram G., McMullen M., Pumiglia K., Aplin AEAdhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 2005;24(21):3459-3471.
10.
Hartwell LH , Kastan MBCell cycle control and cancer. Science. 1994 ;266(5192):1821-1828.
11.
Alonso SR, Ortiz P., Pollan M., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004;164(1):193-203.
12.
Vos CB, Ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJCyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol. 1999;187(3):279-284.
13.
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16):3635-3648.
14.
Straume O., Akslen LAAlterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer. 1997;74(5): 535-539.
15.
Bartkova J. , Lukas J., Guldberg P., et al. The p16-cyclin D/ Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis . Cancer Res. 1996; 56(23):5475-5483.
16.
Grover R., Chana JS, Wilson GD, Richman PI, Sanders R.An analysis of p16 protein expression in sporadic malignant melanoma . Melanoma Res. 1998;8(3):267-272.
17.
Sparrow LE, Eldon MJ, English DR, Heenan PJp16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry . Am J Dermatopathol. 1998; 20(3):255-261.
18.
Rocco JW, Sidransky D.p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res . 2001;264(1):42-55.
19.
Pavey SJ, Cummings MC, Whiteman DC, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res. 2002;12(6):539-547.
20.
Talve L., Sauroja I., Collan Y., Punnonen K., Ekfors T.Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997; 74(3):255-259.
21.
Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P., Sander CAp16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol . 1998;25(6):291-296.
22.
Sanki A., Li W., Colman M., Karim RZ, Thompson JF, Scolyer RAReduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma. Pathology. 2007;39(6):551-557.
23.
Mihic-Probst D., Mnich CD, Oberholzer PA, et al. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2006;118(9):2262-2268.
24.
Mihic-Probst D., Saremaslani P., Komminoth P., Heitz PUImmunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. Virchows Arch. 2003; 443(6):745-751.
25.
Tchernev G. , Orfanos CEDownregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings . J Cutan Pathol. 2007;34(3):247-256.
26.
Recio JA, Noonan FP, Takayama H., et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res. 2002;62(22):6724-6730.
27.
Winnepenninckx V., van den Oord JJp16INK4A expression in malignant melanomas with or without a contiguous naevus remnant: a clue to their divergent pathogenesis?Melanoma Res. 2004;14(4):321-322.
